Plasmore – Next Generation Blood Plasma Protein Aggregation Control

For decades, blood plasma proteins are known and widely used as effective therapeutic products. In order to increase this potential, plasma pools need to be further investigated, fractionated and processed. During this process starting from the plasma donation, freezing and thawing of the frozen plasma, and the entire fractionation process until the final product, a robust temperature control is necessary to avoid protein activation and aggregation. PreviPharma is a specialist for medical research and plasma fractionation processes. Fraunhofer PAMB is specialised in bespoke technological solutions to biomedical applications. Together, we plan to improve temperature profiling in the fractionation process and develop innovative solutions for getting more out of every litter of plasma.

Tandem 9 Plasmore NEU